Related by context. All words. (Click for frequent words.) 80 nonfatal stroke 80 nonfatal MI 79 nonfatal myocardial infarction 78 HF hospitalization 75 cardiovascular hospitalization 75 myocardial infarction MI 75 reinfarction 74 recurrent ischemia 74 Erythropoietic therapies may 73 resuscitated cardiac arrest 73 cardiovascular hospitalizations 73 cerebrovascular events 72 fatal myocardial infarction 72 repeat revascularization 72 ipsilateral stroke 72 thromboembolic 72 macrovascular events 72 stroke myocardial infarction 72 systemic embolism 72 composite endpoint 71 recurrent DVT 71 symptomatic VTE 71 nonfatal myocardial infarction MI 70 thrombotic events 70 CHD CVD 70 events MACE 70 periprocedural 69 thromboembolic events 69 coronary revascularization 69 myocardial infarction 69 non valvular atrial 69 thromboembolic complications 69 recurrent myocardial infarction 69 unstable angina pectoris 69 arterial thromboembolic events 68 CVD mortality 68 nonfatal pulmonary embolism 68 ischemic cardiovascular 68 thromboembolism 68 ischemic cardiomyopathy 67 NYHA Class II 67 MACCE 67 ischemia driven 67 binary restenosis 67 myocardial infarction ventricular fibrillation 67 LVSD 67 arterial revascularization hospitalization 67 valvular disease 67 tumor lysis syndrome 67 cardiac dysfunction 67 pulmonary embolism PE 66 nonischemic 66 cardiovascular mortality 66 macrovascular 66 Events MACE 66 β blockers 66 microvascular complications 66 ATACAND 66 CNS systemic embolism 66 acute coronary syndromes ACS 66 stroke transient ischemic 66 proximal DVT 66 nondiabetic patients 66 intima media thickness 66 hyperkalemia 66 postoperative AF 66 myocardial infarctions 66 torsades de pointes 66 nonfatal cardiovascular 66 acute ischemic 66 left ventricular hypertrophy 65 recurrent VTE 65 renal dysfunction 65 left ventricular dysfunction 65 LV dysfunction 65 microvascular disease 65 prolonged QT interval 65 refractory ischemia 65 de ath 65 atherothrombotic 65 myocardial ischemia 65 unstable angina 65 atherothrombotic disease 65 definite stent thrombosis 65 hemorrhagic complications 65 hypoxemia 65 neutropenia dehydration dyspnea 65 cerebrovascular accident 65 intracerebral haemorrhage 65 ischemic complications 65 CK MB 65 bypass graft CABG surgery 64 infarctions 64 recurrent venous thromboembolism 64 ventricular fibrillation VF 64 eplerenone 64 revascularisation 64 carotid stenosis 64 rehospitalization 64 death reinfarction 64 target vessel revascularization 64 pyrexia mucositis sepsis febrile 64 acute coronary 64 TAXUS Express Stent 64 symptomatic intracranial 64 PLX STROKE targeting 64 peripheral arterial occlusive disease 64 NSTEMI 64 cardiovascular morbidity 64 artery stenosis 64 noncardiovascular 64 torsade de pointes 64 spinal cord compression 64 VT VF 64 Myocardial infarction 64 preserved ejection fraction 64 tirofiban 64 pericardial effusion 64 colorectal adenoma 63 XIENCE V PROMUS Stent 63 cytopenias 63 coronary revascularization procedures 63 Hypotension 63 nadolol 63 KIF6 carriers 63 morphometric vertebral fractures 63 undergoing coronary artery 63 fibrinolysis 63 coronary stenosis 63 IIIa inhibitor 63 ventricular arrhythmia 63 glycated hemoglobin levels 63 extrapyramidal symptoms 63 left ventricular systolic 63 ARCOXIA 63 postoperative mortality 63 renal insufficiency 63 ventricular tachycardia VT 63 cerebral infarction 63 macrovascular disease 63 revascularization procedures 63 TEAEs 63 discontinuations due 63 revascularizations 63 atherothrombosis 63 Major Adverse Cardiac 63 nonfasting triglycerides 63 platelet reactivity 63 severe exacerbations 63 coronary revascularisation 63 embolic stroke 63 stenoses 63 irbesartan 63 rebleeding 63 variant angina 62 fatal arrhythmic 62 angiotensin converting enzyme inhibitor 62 lightheadedness fainting 62 serum phosphate 62 noncardiac 62 #.#/#.# mmHg [001] 62 ketoacidosis hyperosmolar coma 62 gastrointestinal perforation 62 reintervention 62 Endothelial dysfunction 62 recurrent ischemic 62 carotid intima media 62 paclitaxel eluting stents 62 acute myocardial infarction AMI 62 Primary endpoints 62 cardiogenic shock 62 alanine aminotransferase 62 TAXUS p value 62 rosuvastatin #mg 62 echocardiographic parameters 62 PAOD 62 upper gastrointestinal bleeding 62 unfractionated heparin UFH 62 mL/min/#.# m 2 62 chronic thromboembolic pulmonary 62 intra abdominal abscess 62 thromboses 62 noncardiovascular mortality 62 cirrhosis liver failure 62 β blocker 62 Treatment emergent adverse 62 infarct size 62 hypercholesterolaemia 62 intracranial atherosclerosis 62 peri procedural 62 ventricular tachyarrhythmia 62 liver decompensation 62 atherogenic dyslipidemia 62 acute coronary syndrome 62 periprocedural MI 62 Renal dysfunction 62 ventricular dysfunction 62 decompensated heart failure 62 SSc 62 serum creatinine levels 62 salmeterol HFA MDI 62 QT prolongation 62 baseline serum creatinine 62 cerebrovascular 62 severe neutropenia 62 recurrent coronary 62 hypercalcemia 62 hepatic failure 62 angina chest 62 silent ischemia 61 fatal IHD 61 secondary efficacy endpoint 61 thrombo embolic 61 keloid scarring treatment 61 everolimus eluting stents 61 cerebrovascular accidents 61 subclinical hypothyroidism 61 neointimal hyperplasia 61 electrolyte abnormalities 61 simvastatin ezetimibe 61 thyrotoxicosis 61 angioplasty stenting 61 coronary intervention 61 deep venous thromboses 61 beta blockers ACE inhibitors 61 severe hypoglycemic 61 heparin induced thrombocytopenia 61 Hemorrhagic stroke 61 thrombotic complications 61 enoxaparin 61 rhythm disturbances 61 myocardial infarction congestive heart 61 cardiovascular calcification 61 SCr 61 occlusive disease 61 angina pectoris 61 Stent thrombosis 61 LV ejection fraction 61 serum calcium levels 61 macrovascular complications 61 Myocardial Infarction Study 61 arterial thromboembolic 61 pulmonary capillary wedge 61 patients undergoing CABG 61 graft occlusion 61 QTc prolongation 61 myocardial fibrosis 61 carotid artery blockage 61 Torsades de Pointes 61 aspartate aminotransferase AST 61 NATRECOR R 61 x ULN 61 lipid lowering agents 61 NNT = 61 serum aminotransferase levels 61 elevated IOP 61 postoperative complication 61 PSADT 61 histologic subtype 61 VIIBRYD 61 ischemic cerebrovascular 61 cerebrovascular disease 61 atherosclerotic cardiovascular disease 61 events thrombocytopenia neutropenia 61 oral hypoglycemic agents 61 symptomatic pulmonary embolism 61 revascularisation procedures 61 endarterectomy 61 undergoing CABG 61 proliferative diabetic retinopathy 61 aspirin clopidogrel 61 unknown etiology 61 nonvertebral fracture 61 XIENCE V demonstrated 61 Diabetic nephropathy 61 pioglitazone HCl 61 hematologic adverse 61 pericardial effusions 61 glycosylated hemoglobin HbA1c 61 hypoglycemic events 61 confirmed thrombotic cardiovascular 61 NATRECOR ® 61 perioperative mortality 61 cardiovascular disease CVD 61 endometrial hyperplasia 61 dysglycemia 61 GP IIb IIIa inhibitors 61 intracerebral hemorrhage ICH 61 urgent coronary revascularization 61 acute myocardial infarctions 61 primidone 61 nonfasting triglyceride levels 60 defibrillator CRT D 60 ST elevation myocardial 60 hypertension congestive heart 60 antiphospholipid syndrome 60 cerebral vasospasm 60 intracranial bleeding 60 cardioembolic 60 candesartan cilexetil 60 carotid endarterectomy CEA 60 EXJADE 60 arterial thrombotic 60 stable angina 60 asymptomatic carotid stenosis 60 unfractionated heparin 60 microalbuminuria 60 myocardial ischaemia 60 cholecystitis 60 nicardipine 60 dysrhythmias 60 Atherosclerotic 60 induce orthostatic hypotension 60 carotid IMT 60 arrhythmogenic 60 hyperacute 60 dalteparin 60 thyrotropin levels 60 benazepril 60 serum phosphorous 60 Thrombolysis 60 sustained ventricular tachycardia 60 venous thromboembolism 60 thromboembolic disorders 60 anaphylactoid 60 atherosclerotic disease 60 arterial thrombosis 60 venous thromboembolic events 60 locoregional recurrence 60 cardiac tamponade 60 XIENCE V vs. 60 vertebral fracture 60 intracranial hemorrhage ICH 60 MIs 60 cerebral embolism 60 abdominal adiposity 60 angiotensin converting enzyme inhibitors 60 nontraumatic 60 acute decompensation 60 thrombotic 60 fatal pulmonary embolism 60 diastolic blood pressures 60 systolic dysfunction 60 metabolic acidosis 60 VTEs 60 troponin T 60 aneurysmal subarachnoid hemorrhage 60 multivariate adjustment 60 angiographic restenosis 60 Renal impairment 60 LVEF 60 TAXUS Liberte Long 60 angina myocardial infarction 60 advanced adenoma 60 hypercalcaemia 60 prespecified secondary 60 ARIXTRA 60 aminotransferases 60 ischemic 60 Severe hypoglycemia 60 cardiovascular ischemic 60 ACEI ARB 60 peripheral sensory neuropathy 60 aplastic anemia AA 60 Uncontrolled hypertension 60 nephrotoxicity 60 Pulmonary hypertension 60 contrast induced nephropathy 60 Prehypertension 60 Lp PLA2 60 Coronary artery disease 60 ximelagatran 60 Proteinuria 60 TNF antagonist 60 generalized edema 60 fractional shortening 60 hepatorenal syndrome 60 NMIBC 60 ABCB1 60 ICD implantation 60 Ischemic stroke 60 Myocardial Infarction 60 metastatic GIST 60 cerebral vascular disease 60 acute aortic dissection 60 intimal hyperplasia 60 Percutaneous Coronary Intervention 60 neutropenia thrombocytopenia 60 Unstable Angina 60 aspirin heparin 60 hyperglycaemia 60 haematologic 60 peripheral artery 60 patients undergoing percutaneous 60 treatment emergent adverse 60 lacunar 60 Postoperative complications 60 Subarachnoid hemorrhage 60 TMP SMX 60 Ischemic 60 thrombocytopenic 60 nonalcoholic steatohepatitis 60 arterial revascularization 60 MULTAQ 60 HMG CoA reductase inhibitors 60 fulminant hepatic failure 60 dyslipidaemia 60 cerebral ischemia 60 J Am Coll 60 endometrial carcinoma 59 fluvastatin 59 prospectively defined 59 gastric cardia 59 neurologic complications 59 malignant neoplasm 59 tolvaptan 59 CV thrombotic 59 Angiograms carry slight 59 hypercalciuria 59 enalapril 59 NIHSS score 59 Pulmonary embolism 59 paroxysmal AF 59 artery occlusion 59 leucopenia 59 postoperative infections 59 creatinine clearance 59 bivalirudin 59 eptifibatide 59 perioperative complications 59 ST Segment Elevation 59 RE LY ® 59 thromboembolic disease 59 fatal hemorrhagic 59 diabetes dyslipidemia 59 confidence interval #.#-#.# 59 Sezary syndrome 59 biochemical recurrence 59 target lesion revascularization 59 stent implantation 59 ejection fractions 59 oral antidiabetic medication 59 Taxus Stent 59 ventricular remodeling 59 administered erythropoiesis stimulating 59 microbleeds 59 intracerebral 59 % AST SGOT 59 Operative mortality 59 hematologic toxicity 59 intraoperative complications 59 necrotizing pancreatitis 59 pulmonary artery banding 59 cerebrovascular adverse 59 anticoagulants blood thinners 59 valvular 59 STRIDE PD 59 coronary heart 59 Hb A1C 59 angiotensin II receptor blockers 59 autonomic dysfunction 59 antiplatelet medications 59 atherothrombotic events 59 neonatal morbidity 59 Hemorrhagic strokes 59 ischemic stroke 59 beta blocker therapy 59 CTEPH 59 infarction NSTEMI 59 VTE 59 postoperative morbidity 59 LOVENOX 59 cardiovascular disease hypertension 59 prednisone prednisolone 59 adrenal insufficiency 59 Crohn Disease Activity 59 olmesartan 59 revascularization procedure 59 Peripheral arterial disease 59 syncopal 59 TNF blocker therapy 59 atherosclerosis myocardial infarction 59 hypertension dyslipidemia 59 supraventricular arrhythmias 59 tHcy 59 nondiabetics 59 thrombolytic therapy 59 hyperphenylalaninemia HPA due 59 diabetes mellitus hypertension 59 comorbid conditions 59 thrombolytic agents 59 anemia neutropenia 59 vasculopathy 59 dose atorvastatin 59 ipsilateral breast 59 cTnT 59 ACTOplus met XR 59 coagulopathy 59 androgen deprivation 59 wound dehiscence 59 acute myocardial infarction 59 % CI #.#-#.# [006] 59 infarction STEMI 59 aldosterone antagonist 59 Venous thromboembolism 59 antiplatelet agent 59 serum triglycerides 59 nonvertebral fractures 59 catheter occlusion 59 revascularization 59 renal artery stenosis 59 antithrombotic therapy 59 thrombophlebitis 59 lipid lowering drugs 59 PRADAXA #mg 59 anaphylactoid reactions 59 artery reclogging 59 Ischemic heart 59 intravesical therapy 59 hallucinations dyskinesia 59 cardioembolic stroke 59 serious cardiovascular thrombotic 59 nonsignificant 59 multivessel disease 59 NYHA Class III 59 progressive dyspnea 59 cryptogenic stroke 59 systemic corticosteroid 59 CrCl 59 Tasigna prolongs 59 hypoperfusion 59 cTnI 59 superficial femoral 59 #mmHg [001] 59 acutely decompensated congestive heart 59 advanced adenomas 59 atherosclerotic cardiovascular 59 nasopharyngitis headache 59 cerebrovascular ailments 59 intraventricular hemorrhage 59 serum potassium 59 ischaemia 59 carotid artery stenting CAS 59 ACTOplus met 59 concomitant medications 59 Primary Hypercholesterolemia 59 carotid artery intima media 59 hsCRP 59 Coronary artery calcification 59 cilostazol 59 CABG coronary artery 59 coronary artery disease 59 clinically meaningful reductions 59 perioperatively 59 angioplasties stents 59 reoperations 59 drug eluting stent implantation 59 intravenous bisphosphonates 59 dermatologic reactions 59 elevated ALT 59 asymptomatic PAD 59 Infusion Reactions Severe 59 hypopneas 59 antiarrhythmic drug 59 Ventricular Tachycardia 59 vein thrombosis 59 macroalbuminuria 59 coinfected patients 59 venous thrombosis 59 haemorrhagic stroke 59 cardiovascular 59 variceal hemorrhage 59 mucocutaneous reactions 59 ACTOS ® 59 thickness CIMT 59 arterial calcification 59 plus glycoprotein IIb 59 headache nasopharyngitis 59 CYPHER Stent 59 variceal bleeding 59 residual platelet reactivity 59 Lactic acidosis 59 CHD mortality 59 interstitial pneumonitis 59 prasugrel uh prevented 59 Arrhythmogenic Right Ventricular Cardiomyopathy 59 prostate TURP 59 myocardial infarctions MIs 59 elevated LDL cholesterol 59 dyslipidemia hypertension diabetes 59 lung esophageal 59 atrioventricular block 59 fulminant hepatitis 59 hemodynamically significant 59 stroke hypertension palpitations 59 transurethral resection 59 subtrochanteric 59 valvular heart disease 59 serum uric acid 59 confidence interval CI 59 venous thromboembolic disease 58 intact parathyroid hormone 58 anthracycline taxane 58 adenomatous polyps 58 systolic hypertension 58 pulmonary exacerbations 58 vascular inflammation 58 diameter stenosis 58 cerebrovascular diseases 58 postoperative pulmonary 58 TAXUS Stent 58 percutaneous transluminal coronary angioplasty 58 lumiracoxib 58 pretransplant 58 clopidogrel 58 Nesiritide 58 cardiac biomarkers 58 aspartate aminotransferase 58 hypotension 58 Val HeFT 58 mitral stenosis 58 intracranial stenosis 58 oxycodone CR 58 hyperalgesia 58 antithrombotic therapies 58 lispro 58 obstructive coronary 58 incidence ≥ 58 pheochromocytoma 58 graft dysfunction 58 apnea hypopnea 58 mycophenolate mofetil 58 Hypertrophic cardiomyopathy 58 cardiac repolarization 58 secondary hyperparathyroidism 58 hypertension hypercholesterolemia 58 ischemic vascular 58 mcg QD 58 hepatic cirrhosis 58 proliferative retinopathy 58 postoperative atrial fibrillation 58 coagulation abnormalities 58 venous thromboembolisms 58 variceal 58 Known hypersensitivity 58 Lp PLA 2 58 cardiomegaly 58 pyelonephritis 58 serum calcium 58 lipid elevations 58 malignant neoplasms 58 Hazard Ratio 58 bone marrow suppression 58 elevated fasting glucose 58 retinal vein occlusion induced 58 hemodynamic instability 58 QTc intervals 58 DES implantation 58 carotid plaque 58 onset diabetes mellitus 58 cholelithiasis 58 cytoreductive surgery 58 pulmonary dysfunction 58 abnormal lipids 58 neutrophil counts 58 pT3 58 cerebral perfusion 58 HES CEL 58 unstable angina UA 58 nonhematologic adverse reactions 58 intracerebral hemorrhage 58 Digoxin toxicity 58 artificial arteriovenous dialysis 58 thickness IMT 58 overt nephropathy 58 landmark ATHENA trial 58 inhospital 58 baseline HbA1c 58 thrombogenic 58 hypokalemia 58 antiplatelet agents 58 beclomethasone dipropionate 58 hepatotoxicity 58 diastolic BP 58 peripheral edema 58 HbA 1c levels 58 arrhythmogenic right 58 QRS duration 58 left ventricular LV 58 CYPHER ® Stent 58 elevated triglyceride levels 58 cyclophosphamide methotrexate 58 myopathy rhabdomyolysis 58 sirolimus stent 58 mixed hyperlipidemia 58 lactate dehydrogenase LDH 58 post thrombotic syndrome 58 lactic acidosis 58 nonfatal cardiac arrest 58 apo B 58 cerebral vascular 58 #mm Hg 58 carotid artery stenosis 58 plus GP IIb 58 IOP lowering 58 systemic hypotension 58 Orthostatic hypotension 58 undergoing coronary angiography 58 pathological fractures 58 renal impairment 58 radical nephrectomy 58 Acute coronary syndromes 58 chronic metabolic acidosis 58 albuminuria 58 Arch Intern Med 58 malperfusion 58 postoperative complications 58 dysfunction LVSD 58 myocardial infarct 58 hemolysis 58 Unstable angina 58 sotalol 58 Diabetic Mellitus 58 mm Stent 58 autoantibody levels 58 BYSTOLIC 58 nonobstructive CAD 58 sirolimus eluting stents 58 fibrosis scarring 58 subarachnoid hemorrhages 58 flutamide 58 acute coronary syndromes 58 atrial arrhythmias 58 somnolence dizziness 58 anaphylactic reactions bronchospasm 58 transferrin saturation 58 intracerebral hemorrhages 58 rFVIIa 58 antiplatelet drugs 58 glomerular filtration 58 urolithiasis 58 bowel perforations 58 plasma creatinine 58 % CI #.#-#.# [001] 58 receiving VELCADE 58 serum creatinine 58 papillary renal cell carcinoma 58 colorectal carcinoma 58 venous thromboembolic 58 retransplantation 58 bleeding ulceration 58 elevated serum creatinine 58 atherosclerotic vascular disease 58 D dimer 58 unfavorable prognostic 58 FluCAM arm 58 See WARNINGS 58 irregular quivering 58 stent thromboses 58 NYHA class 58 PSA nadir 58 ventricular tachyarrhythmias 58 thromboprophylaxis 58 COPD exacerbation 58 P = .# 58 leiomyomas 58 multivariable adjusted 58 uncontrolled hypertension 58 NYHA functional class 58 creatinine ratio 58 hypophosphatemia 58 aneurysm rupture 58 recombinant tissue plasminogen 58 proteinuria 58 valsartan 58 serum urate 58 mild renal insufficiency 58 vasospasm 58 UA NSTEMI 58 pacemaker implantation 58 estimated glomerular filtration 58 pulmonary thromboembolism 58 optic neuropathy 58 elevated lipase 58 liver transplant recipients 58 Treatment discontinuations due 58 atherosclerotic CVD 58 glomerular filtration rate 58 peptide BNP 58 Left ventricular hypertrophy 58 postoperative delirium 58 systemic corticosteroids 58 obstructive CAD 58 Lupus nephritis 58 clazosentan 58 neoadjuvant 58 N telopeptide 58 hip BMD 58 blindness renal failure 58 non selective NSAIDs 58 pretest probability 57 creatine kinase MB 57 mitral regurgitation MR 57 hepatic insufficiency 57 extracranial 57 polyp recurrence 57 hepatocellular carcinoma liver 57 atherosclerotic 57 asthma exacerbation 57 liver histology 57 fasting glucose levels 57 Ribavirin causes 57 QT intervals 57 ECG abnormalities 57 unresectable tumors 57 aminotransferase ALT 57 echocardiographic 57 hyperhomocysteinemia 57 gastrointestinal perforations 57 impaired glucose metabolism 57 subclinical hyperthyroidism 57 mucosal inflammation 57 granulomatous 57 infarcts 57 Vidaza ® 57 coronary 57 systemic autoimmune 57 Febrile neutropenia 57 metastatic malignant 57 liver metastasis 57 1mg dose 57 pathologic fracture 57 anti arrhythmic drugs 57 recurrent stroke 57 Cypher Stent 57 carotid endarterectomy 57 #mg/dL [001] 57 hypocalcemia 57 ID TLR 57 atrioventricular valve 57 corrected QT interval 57 plasma triglycerides 57 nadroparin 57 distensibility 57 aldosterone antagonists 57 nocturnal hypoglycaemia 57 salmeterol fluticasone propionate 57 ventricular septum 57 arteries atherosclerosis 57 coronary stenoses 57 PRADAXA 57 intrathoracic 57 lipoprotein levels 57 hormone receptor negative 57 mmHg diastolic 57 ACUITY trial 57 multivariate Cox 57 activated partial thromboplastin 57 Hemorrhagic 57 #mg BID [003] 57 leukopenia 57 triglyceride TG 57 severe hypoglycemia 57 carotid atherosclerosis 57 ß blockers 57 syncope fainting 57 arterial thickening 57 febrile neutropenia 57 lower extremity amputation 57 heart arrhythmias 57 mild renal impairment 57 urgent revascularization 57 intravitreal injections 57 symptomatic hyponatremia 57 SLNB 57 ertapenem 57 hypervolemic hyponatremia 57 events TEAEs 57 TAVR 57 postoperative chemotherapy 57 diabetic kidney 57 adenoma recurrence 57 perindopril 57 T2DM 57 tachyarrhythmias 57 salmeterol inhalation powder 57 verapamil 57 dilated cardiomyopathy DCM 57 subclinical atherosclerosis 57 metformin accumulation 57 invasive ductal 57 Secondary efficacy endpoints 57 transplantation HCT 57 arrythmias 57 hypoventilation 57 metformin sulfonylurea 57 elevated uric acid 57 cardiomyopathies 57 HIV HCV coinfected 57 platelet activation 57 noncardiac surgery 57 paroxysmal atrial fibrillation 57 hepatic dysfunction 57 generalized seizures 57 serum phosphorus 57 acute cholecystitis 57 death dissection perforation 57 ADHF 57 bronchial hyperresponsiveness 57 hypertension diabetes mellitus 57 VTE prophylaxis 57 Carvedilol 57 ng dL 57 fibrinolytic 57 thiazide diuretic 57 p = NS 57 gallbladder disease 57 ruboxistaurin 57 fluid overload 57 vertebrobasilar 57 Idiopathic pulmonary fibrosis 57 alpha interferons 57 ischemic heart 57 severe mitral regurgitation 57 Atrial fibrillation AF 57 fraction LVEF 57 transthoracic 57 gastric varices 57 elevated transaminases 57 unresectable HCC 57 histologically confirmed 57 fainting lightheadedness 57 endothelial activation 57 dyslipidemia hypertension 57 Restenosis 57 radiotherapy RT 57 onset atrial fibrillation 57 fragility fracture 57 parecoxib 57 hypomagnesemia 57 PREZISTA r arm 57 bullous 57 lipid parameters 57 4mg/kg 57 preoperative PSA 57 lenalidomide dexamethasone 57 coronary atherosclerosis 57 coronary interventions 57 hypercoagulable 57 NSTE ACS 57 stent thrombosis blood clots 57 total cholesterol triglycerides 57 symptomatic DVT 57 angiographically 57 dronedarone 57 adjunctive placebo 57 albumin excretion rate 57 distant metastasis 57 mcg BID 57 HeFH 57 decompensation 57 EBRT 57 idraparinux 57 Albuminuria 57 lymph node metastasis 57 elevated hsCRP 57 afterload 57 cystic fibrosis chronic pancreatitis 57 cardiovascular cerebrovascular 57 CsA 57 Warfarin Coumadin 57 ticagrelor 57 serum triglyceride levels 57 Ischemic strokes 57 thrombocytosis 57 Auxilium anticipates 57 liver resection 57 Exclusion criteria 57 elevated triglycerides 57 retinopathy nephropathy 57 colectomy 57 PNH patients 57 loop diuretics 57 coronary artery calcification 57 adenomatous 57 receiving INTRON 57 Navelbine 57 Thrombocytopenia 57 eGFR 57 distal embolization thrombus formation 57 gastroduodenal 57 MADIT II 57 highest tertile 57 cystatin C 57 thrombocytopenia neutropenia 57 hypoglycaemic episodes 57 Intracerebral hemorrhage 57 severe hypersensitivity reactions 57 percutaneous intervention